Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Leptomeningeal metastasis (LM), also known as leptomeningeal carcinomatosis (LC), is a
devastating complication of metastatic cancer that occurs when neoplastic cells invade the …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

PURPOSE Photon involved-field radiotherapy (IFRT) is the standard-of-care radiotherapy for
patients with leptomeningeal metastasis (LM) from solid tumors. We tested whether proton …

Background Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …

PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …

Brain metastases (BMs) represent the most frequent event during the course of Non-Small
Cell Lung Cancer (NSCLC) disease. Recent advancements in the diagnostic and …

Introduction Patients with NSCLC with leptomeningeal metastases (LM) presented dismal
prognosis. Cerebrospinal fluid (CSF) is suggested as a medium of liquid biopsy of LM …

Objectives Osimertinib has been reported to be effective against central nervous system
(CNS) metastasis from activating EGFR mutation-positive NSCLC. Nevertheless, the true …